Literature DB >> 3132310

Controversies in the management of febrile neutropenic cancer patients.

M Rubin1, J W Hathorn, P A Pizzo.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3132310     DOI: 10.3109/07357908809077045

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


× No keyword cloud information.
  15 in total

1.  Multicentre Canadian clinical trials on neutropenic patients.

Authors:  R Feld
Journal:  Can J Infect Dis       Date:  1992-03

2.  Risk assessment and risk-based therapy in febrile neutropenic patients.

Authors:  K V Rolston
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-07       Impact factor: 3.267

Review 3.  Outpatient therapy for febrile neutropenia: clinical and economic implications.

Authors:  Fausto de Lalla
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 4.  Outpatient antibiotic treatment in low-risk febrile neutropenic cancer patients.

Authors:  C P Escalante; E B Rubenstein; K V Rolston
Journal:  Support Care Cancer       Date:  1996-09       Impact factor: 3.603

Review 5.  Common emergencies in cancer medicine: infectious and treatment-related syndromes, Part I.

Authors:  C R Thomas; L V Wood; J G Douglas; K J Stelzer; W Koh; R Panicker
Journal:  J Natl Med Assoc       Date:  1994-10       Impact factor: 1.798

Review 6.  The role of colony-stimulating factors and granulocyte transfusion in treatment options for neutropenia in children with cancer.

Authors:  Der-Cherng Liang
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

7.  Three-step empiric treatment for severely neutropenic patients with fever: ceftazidime--vancomycin--amphotericin B.

Authors:  H Koeppler; K H Pflueger; R Seitz; K Havemann
Journal:  Infection       Date:  1989 May-Jun       Impact factor: 3.553

8.  Once daily antibiotic regimen in paediatric oncology.

Authors:  E Bouffet; C Fuhrmann; D Frappaz; D Couillioud; V Artiges; C Charra; D Bouhour; M Brunat Mentigny
Journal:  Arch Dis Child       Date:  1994-06       Impact factor: 3.791

9.  Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice.

Authors:  Helen Innes; Sheow Lei Lim; Allison Hall; Su Yin Chan; Neeraj Bhalla; Ernest Marshall
Journal:  Support Care Cancer       Date:  2007-09-25       Impact factor: 3.603

Review 10.  Outpatient management of febrile episodes in neutropenic cancer patients.

Authors:  E B Rubenstein; K Rolston
Journal:  Support Care Cancer       Date:  1994-11       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.